Unilabs achieves increased revenues for the year ended May 31, 2007

18 september 2007 * Revenues of CHF 313.9 million, up 7.8% * EBITDA of CHF 51.6 million, up 12.6% * Earnings before taxes of CHF 24.1 million, up 11.3% * Net income of CHF 9.1 million, down 8.7% For the fiscal year 2006/2007, which ended on May 31, 2007, Unilabs (SWX: ULB) achieved revenues of CHF 313.9 million, an increase of 7.8% compared with CHF 291.3 million in the previous financial year. At constant exchange rates, revenues grew by 6.4%. Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased by 12.6% to reach CHF 51.6 million, or 16.5% of revenues, while operating profit increased by 4.9% to CHF 35.6 million. This result partially reflects the impact of the Swiss Federal Council to impose a 10% linear reduction in the reimbursement prices for tests, beginning January 1, 2006. Net income attributable to Unilabs shareholders reached CHF 9.1 million, a decrease of 8.7%. Fourth quarter revenues reached CHF 87.5 million, up 9.3% from CHF 80.1 million for the same quarter one year ago. EBITDA reached CHF 18.9 million, up 25.8% or 21.6% of revenues compared with CHF 15.0 million or 18.8% of revenues in the previous year. As a result of the 10% linear reduction in the reimbursement prices for tests which took effect on January 1, 2006, full year revenues in Switzerland, Unilabs' largest market, decreased by 3.5% to CHF 178.9 million versus CHF 185.4 million in the previous year. The cost-cutting measures implemented by Unilabs partially compensated this negative impact. These measures resulted in annual cost savings of CHF 8.6 million during the year. Excluding the impact of the 10% price cut, Swiss revenues would have increased by 2.6% during the full year. Revenues grew by 21.0 % in Spain to CHF 47.0 million and by 3.9% in France to CHF 49.5 million. As a result of its successful entry in the Portuguese market in the previous fiscal year, Unilabs posted revenues of CHF 26.8 million, a very significant increase due to the several acquisitions in this country during the last twelve months. For the full fiscal year 2006/2007, earnings before interest, taxes, depreciation and amortisation (EBITDA) increased by 12.6% to reach CHF 51.6 million, or 16.5% of revenues. Operating profit (EBIT) reached CHF 35.6 million, or 11.3% of revenues, compared with CHF 33.9 million, or 11.6% of revenues in the previous fiscal year, an increase of 4.9%. Earnings before taxes increased by 11.3% to CHF 24.1 million, compared with CHF 21.7 million in the previous financial year. Income taxes increased from CHF 7.7 million to CHF 11.9 million, an increase of 54.7%. Taking into account higher income taxes, net income attributable to Unilabs shareholders amounted to CHF 9.1 million (or CHF 0.95 per bearer share), compared with CHF 9.9 million (or CHF 1.01 per bearer share) in the previous financial year. Strong balance sheet and debt position At May 31, 2007, total stockholders' equity grew to CHF 139.1 million versus CHF 130.7 million in the previous year, an increase of 6.5%. Cash provided by operations reached CHF 28.5 million compared with CHF 32.7 million in the previous fiscal year. As a result of acquisitions, the net financial debt increased by 57.7% from CHF 72.4 million to CHF 114.1 million during the period. Unused credit facilities and available cash increased from CHF 29.4 million last year to CHF 64.5 million on May 31, 2007. During the year ended May 31, 2007, Unilabs: * Completed five acquisitions in Portugal, and one in Switzerland * Consolidated its market share in Switzerland, Spain, Portugal and France * Implemented cost cutting measures that resulted in annual cost savings of CHF 8.6 million * Pursued the identification and review of acquisition targets * Pursued the construction of its new production platform in Coppet, Switzerland Outlook For the current fiscal year, ending May 31, 2008, Unilabs expects an organic Group revenue growth of 4% in local currencies and anticipates an EBITDA margin between 17-18% of revenues. Conference call Unilabs will hold a conference call today at 15:30 CET to discuss the financial results for the full fiscal year. To participate in the conference call, dial: +41 (0)91 610 56 00 (Europe and Switzerland), +44 (0) 20 7107 06 11 (UK), +1 (1) 866 291 41 66 (US). Digital playback is available for 48 hours after the conference starting at 18:30 p.m. until 20 September 18:30 p.m. CET, dial: +41 91 612 43 30 (Europe); +44 207 108 62 33 (UK); +1 866 416 25 58 (US/Canada); Conference ID: 214 followed by #. In order to view the slide presentation, a link to the presentation will be provided immediately prior to the event on www.unilabs.com. Please note that sound will only be provided through the telephone conference. About Unilabs The Unilabs Group (SWX: ULB) is the European leader of clinical testing laboratories. With over 50 laboratories and over 1800 employees operating in 6 countries, Unilabs tests over 3.5 million samples per year using more than 1500 different tests. Unilabs' clinical testing services are used by over 60 public and private hospitals in France, Spain and Switzerland. Unilabs has been listed on the SWX Swiss Stock Exchange since 1997. Edgard Zwirn, Executive Chairman, is at your disposal for any further query (tel. +4122 909 77 77). Our press releases are also available on the Internet at our web site www.unilabs.com. --- End of Message --- Unilabs SA C.P. 2559 Genève 1 WKN: 906648; ISIN: CH0012561640; Index: SPI, SSCI, SBIOM, SLIFE, SPIEX; Listed: Main Market in SWX Swiss Exchange;